Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Phase II Therapeutic Eribulin provided

Transcription

1 FOR MORE ABOUT OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT THE OHC RESEARCH DEPARTMENT AT Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Eribulin provided BRE- 233: BO28407 I TDM- 1 provided NEOADJUVANT BRE- 197 Eribulin provided NEOADJUVANT, TNBC BRE- 238: M (pending 2 nd Qtr 2014) I Veliparib/Carboplatin provided METASTATIC,, TNBC BRE- 223: ABI MBC- 001 /III Nab- Paclitaxel provided Phase 2 Trial of Eribulin in Patients Who do Not Achieve Pathologic Complete Response (pcr) Following Neoadjuvant Chemotherapy A Randomized, Multicenter, Open- Label Trial Comparing Chemotherapy plus Trastuzumab plus Pertuzumab versus Chemotherapy plus Trastuzumab Emtansine plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2- Positive Primary Breast Cancer A Randomized Study of Eribulin/Cyclophosphamide or Docetaxel/ Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2- Negative Breast Cancer A Randomized, Placebo- Controlled, Double- Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) Phase 2/3, Multi- center, Open- Label, Randomized Study of Weekly Nab- Paclitaxel (ABRAXANE) in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First- Line Treatment in Subjects with ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer Page 1 of 10

2 METASTATIC,, HR+, HER2- BRE- 234: CLEE011A2301 (pending 1 st Qtr 2014) I LEE011 provided METASTATIC, REFRACTORY, ER/PR POSITIVE BRE- 217: CRAD001Y2201 Everolimus provided A Randomized, Double- Blind, Placebo- Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease A Three- Arm, Randomized, Open Label, Study of Everolimus in Combination with Exemestane versus Everolimus Alone versus Capecitabine in the Treatment of Postmenopausal Women with Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer after Recurrence or Progression on prior Letrozole or Anastrozole BRE- 229: MDV Enzalutamide/placebo & Exemestane provided A Phase 2, Randomized, Double- Blind, Placebo- Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination with Exemestane in Patients with Advanced Breast Cancer That is Estrogen or Progesterone Receptor- Positive and HER2- Normal METASTATIC, REFRACTORY, HER2- BRE- 166 Exploratory Trastuzumab/Pertuzumab provided METASTATIC, REFRACTORY, HER2+ BRE- 200 (Phase 1 open at BAM only) Cabazitaxel/Lapatinib provided Use of the PRO Onc Assay HER2 Overexpression and Activation in Patients with Metastatic Breast Cancer Whose Tumors are HER2- Negative by Standard Fish Testing A Study with Lead- In Safety Cohort of Cabazitaxel plus Lapatinib as Therapy for HER2- Positive Metastatic Breast Cancer Patients with Intracranial Metastases METASTATIC, REFRACTORY, TNBC BRE- 222: MDV Enzalutamide provided A Phase 2, Single- Arm, Open- Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients with Advanced, Androgen Receptor- Positive, Triple- Negative Breast Cancer Page 2 of 10

3 METASTATIC, TNBC and GPNMB OVEREXPRESSING, FIRST- OR SECOND- LINE BRE- 231: CDX A (pending 1 st Qtr 2014) A Randomized Multicenter study of CDX- 011 (CR011- vcmmae) in Patients with Metastatic, GPNMB Over- Expressing, Triple- Negative Breast Cancer CDX- 011 provided Colorectal/Rectal Clinical Trials GI- 168 Aflibercept provided A Study of 5- Fluorouracil, Aflibercept, and Radiation in the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer METASTATIC, GI- 181: ML28442 Bevacizumab provided STEAM (Sequencing Triplet with Avastin and Maintenance): FOLFOXIRI/ Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First- Line Metastatic Colorectal Cancer METASTATIC, CACHEXIA GI- 190: PT023 (pending 2 nd Qtr 2014) I MABp1 provided A Pivotal I Study to Evaluate Overall Survival using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients with Cachexia Page 3 of 10

4 Esophageal/Gastric Clinical Trials NEOADJUVANT GI- 166 Lapatinib provided A Study with Lead- In Safety Cohort of 5- Fluorouracil, Oxaliplatin and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2 Positive Esophagogastric Adenocarcinoma GI- 176: YO28322 I Onartuzumab provided GI- 185: BO25114 I Pertuzumab/placebo and Trastuzumab provided A Randomized, I Multicenter, Double- Blind, Placebo- Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with 5- Fluorouracil, Folinic Acid, and Oxaliplatin (mfolfox6) in Patients with Metastatic HER2- Negative, Met- Positive Gastroesophageal Cancer A Double- Blind, Placebo- Controlled, Randomized, Multicenter, I Study Evaluating the Efficacy and Safety of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2- Positive Metastatic Gastroesophageal Junction and Gastric Cancer Hematological Malignancies HEMREF- 31: TGR (pending) Phase I TGR provided A Phase I Dose Escalation Study Evaluating the Safety and Efficacy and to TGR in Patients with Relapsed or Refractory Hematologic Malignancies LYM- 89: GS- US GS provided A Phase 2 Open- Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS in Subjects with Relapsed or Refractory Hematologic Malignancies CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RELAPSED/REFRACTORY CLL- 18 Ofatumumab provided Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia, a Trial Page 4 of 10

5 SECOND- LINE CLL- 30: IPI I IPI- 145 provided A Phase 3 Study of IPI- 145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLL- 31: IPI I IPI- 145 provided A Study of IPI- 145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI (CLL- 30 Rollover Study) CHRONIC MYELOGENOUS LEUKEMIA (CML) SECOND- LINE CML- 18: CA Phase IV Dasatinib provided An Open Label, Randomized Phase IV Study of Dasatinib vs. Imatinib in the Treatment of Subjects with Chronic Phase Chronic Myeloid Leukemia who have not Optimally Responded to 3 Months of Therapy with 400 mg Imatinib HODGKIN S DISEASE LYM- 84: C25003 I Brentuximab provided MULTIPLE MYELOMA MM- 23 Bendamustine/Bortezomib provided RELAPSED/REFRACTORY MM- 27 Phase I/II Panobinostat/Carfilzomib provided A Randomized, Open- Label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin s Lymphoma Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First- Line Treatment of Patients with Multiple Myeloma who are not Candidates for High Dose Chemotherapy Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma Page 5 of 10

6 MYELODYSPLASTIC SYNDROME MDS- 14 Pracinostat provided A Randomized, Placebo- Controlled Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated IPSS Intermediate 1, 2, or high risk myelodysplastic syndrome (MDS) MDS- 15: MEI- 005 Pracinostat provided A Simon Two- Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone NON- HODGKIN S LYMPHOMA - FOLLICULAR RELAPSED/REFRACTORY LYM- 87: IPI IPI- 145 provided A Phase 2 Study of IPI- 145 in Subjects with Refractory Indolent Non- Hodgkin Lymphoma Gynecological Clinical Trials Ovarian SECOND- LINE GYN- 42: EMR _012 Pimasertib/placebo and SAR245409/placebo provided Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR or of Pimasertib with SAR Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer THIRD- LINE GYN- 41: ET743- OVC (pending 1 st Qtr 2013) I Trabectedin, Doxil Provided A Randomized, Open- Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced- Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Page 6 of 10

7 Primary Peritoneal THIRD- LINE GYN- 41: ET743- OVC (pending 1 st Qtr 2013) I Trabectedin, Doxil Provided Fallopian Tube THIRD- LINE GYN- 41: ET743- OVC (pending 1 st Qtr 2013) I Trabectedin, Doxil Provided A Randomized, Open- Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced- Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer A Randomized, Open- Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced- Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Lung Non Small Cell Clinical Trials STAGE IIIB/IV, LUN- 229 OGX- 427 provided Double- Blind Randomized Trial of Carboplatin and Pemetrexed with or without OGX- 427 in Patients with Previously Untreated Stage IV Non- Squamous Non- Small Cell Lung Cancer (Spruce Clinical Trials) LUN- 258: GO28754 MPDL3280A provided A, Multicenter, Single- Arm Study of MPDL3280A in Patients with PD- L1 Positive Locally Advanced or Metastatic Non- Small Cell Lung Cancer METASTATIC, 1 ST - LINE LUN- 263: ABI NSCL- 003 (pending) A I, Randomized, Open- Label, Crossover, Multi- Center, Safety and Efficacy I Study to Evaluate Nab- Paclitaxel (ABRAXANE) as Maintenance Treatment After Induction with Nab- Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Nab- Paclitaxel provided (maint) Non- Small Cell Lung Cancer Page 7 of 10

8 METASTATIC, 2 nd - LINE LUN- 264: PPHM 1202 (pending) I Bavituximab/placebo provided RELAPSED/REFRACTORY LUN- 214 (pending) BKM120 provided LUN- 238: AT AT13387 provided LUN- 240: SPI (On Hold) SPI provided LUN- 247: IB Afatinib provided LUN- 250: GO28625 (Cohort 2 & 3 closed) MPDL3280A provided LUN- 252: I4C- MC- JTBC LY provided LUN- 258: GO28754 MPDL3280A provided SUNRISE: A I, Randomized, Double- Blind, Placebo- Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Second- Line Therapy in Patients with Stage IIIb/IV Non- Squamous Non- Small- Cell Lung Cancer Study of Erlotinib and BKM120 in Patients with Advanced Non- Small- Cell Lung Cancer Previously Sensitive to Erlotinib A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non- Small Cell Lung Cancer (NSCLC) A Multicenter, Randomized, Study of SPI in Combination with Docetaxel for Patients with Non Small Cell Lung Cancer after Failure of First- Line Platinum- Based Chemotherapy A IB, Non- Randomized, Open- Label, Two- Cohort Study in Patients with EGFR Mutations- Positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM) A, Multicenter, Single- Arm Study of MPDL3280A in Patients with PD- L1 Positive Locally Advanced or Metastatic Non- Small Cell Lung Cancer (Alpha) A Randomized, Open- Label Phase 2 Study Evaluating LY Plus Erlotinib and LY Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib A, Multicenter, Single- Arm Study of MPDL3280A in Patients with PD- L1 Positive Locally Advanced or Metastatic Non- Small Cell Lung Cancer Page 8 of 10

9 Lung Small Cell Clinical Trials LUN- 223: CA I Ipilimumab provided Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum versus Placebo plus Etoposide/ Platinum in Subjects with Newly Diagnosed Extensive- Stage Disease Small Cell Lung Cancer (ED- SCLC) Pancreas Clinical Trials ADJUVANT GI- 194: ABI PANC- 003 (pending 2 nd Qtr) I Nab- Paclitaxel provided A Phase 3, Multicenter, Open- Label, Randomized, Study of nab- Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma GI- 179: EMR I TH- 302/placebo provided GI- 184 OGX- 427 provided A Randomized, Double- Blind, I Study of the Efficacy and Safety of Gemcitabine in Combination with TH- 302 Compared with Gemcitabine in Combination with Placebo in Previously Untreated Subjects with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma A Randomized, Double- Blinded Trial of Gemcitabine Plus Nab- Paclitaxel Combined with OGX- 427 or Placebo in Patients with Metastatic Pancreatic Cancer (The Rainer Trial) Melanoma Clinical Trials ADJUVANT MEL- 31: BRF I Dabrafenib/Trametinib provided A I, Randomized, Double- Blind Study of Dabrafenib (GSK ) in Combination with Trametinib (GSK ) versus Placebo in the Adjuvant Treatment of High- Risk BRAF V600E/K Mutation- Positive Melanoma after Surgical Resection Page 9 of 10

10 Prostate Clinical Trials METASTATIC, GU- 109: XL (pending 2 nd Qtr 2014) Cabozantinib (XL184) provided A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy- Naïve Subjects with Bone- Metastatic Castration- Resistant Prostate Cancer METASTATIC, SECOND- LINE GU- 92: OGX I Custirsen provided Randomized, Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX- 011) to Cabazitaxel/Prednisone for Second- Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer Renal Clinical Trials METASTATIC, GU- 108: WO29074 (pending 1 st Qtr 2014) MPDL3280A/Bevacizumab provided A, Randomized Study of MPDL3280A Administered as Monotherapy or in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma Page 10 of 10